Muro, K., Jen, M., & Cheng, R. (2019). Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data. Cancer Manag Res.
Citação norma ChicagoMuro, Kei, Min-Hua Jen, and Rebecca Cheng. "Is Ramucirumab and Paclitaxel Therapy Beneficial for Second-line Treatment of Metastatic Gastric or Junctional Adenocarcinoma for Patients With Ascites? Analysis of RAINBOW Phase 3 Trial Data." Cancer Manag Res 2019.
Citação norma MLAMuro, Kei, Min-Hua Jen, and Rebecca Cheng. "Is Ramucirumab and Paclitaxel Therapy Beneficial for Second-line Treatment of Metastatic Gastric or Junctional Adenocarcinoma for Patients With Ascites? Analysis of RAINBOW Phase 3 Trial Data." Cancer Manag Res 2019.